CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient

Bulletin Express

05/26

CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.

The trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).

PCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.

The company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1149227006"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149227006\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149227006?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 08:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149227006","market":"hk","top_or_hot":-1,"title":"CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.</p>\n<p>The trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).</p>\n<p>PCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.</p>\n<p>The company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-26 08:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.</p>\n<p>The trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).</p>\n<p>PCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.</p>\n<p>The company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1149227006","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149227006","pubTimestamp":1779755154,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物启动24价肺炎球菌结合疫苗PCV24 I/II期试验，入组首例患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.\nThe trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).\nPCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.\nThe company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}